← Back to Search

Antidepressant

The MATCH (Medication Aids for Tobacco Cessation and Health) Study (MATCH Trial)

N/A

Waitlist Available

Led By Laurie Zawertailo, PhD

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up upon first patient enrolled and 1 month following last patient enrolled

Awards & highlights

All Individual Drugs Already Approved

Approved for 5 Other Conditions

No Placebo-Only Group

Summary

Clinically proven medications such as nicotine replacement therapy, bupropion and varenicline are available to help smokers quit but there are not widely used. The primary objective of this study is to evaluate the real-world long-term effectiveness of of bupropion and varenicline treatment in a community sample of smokers interested in quitting. The investigators hypothesize that varenicline treatment will result in higher quit rates at end of treatment and at one year after treatment compared to bupropion. Smoking status will be biochemically confirmed at various time points using salivary cotinine measures. Furthermore, since 50% of the variation in quit success is genetically determined, and the effectiveness of different cessation medication may differ considerably in sub-groups of smokers carrying certain genetic variants, the investigators will collect saliva samples from consenting participants to evaluate the moderating effect of genetics on treatment response.

Eligible Conditions

Tobacco Use Disorder
Smoking Addiction

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ upon first patient enrolled and 1 month following last patient enrolled

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~upon first patient enrolled and 1 month following last patient enrolled

This trial's timeline: 3 weeks for screening, Varies for treatment, and upon first patient enrolled and 1 month following last patient enrolled for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in smoking status over time

Secondary study objectives

Continuous Abstinence

Pre-post Decisional Balance Scores

Other study objectives

Genetic Polymorphisms

Personality Traits

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 5 Other Conditions

This treatment demonstrated efficacy for 5 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: VareniclineExperimental Treatment2 Interventions

Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.

Group II: BupropionExperimental Treatment2 Interventions

Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bupropion

FDA approved

Varenicline

FDA approved

Weekly Motivational Emails

2014

N/A

~970